CLAIMS

WHAT IS CLAIMED IS:

1. A method of simultaneously treating hypertension, hypertriglyceridemia, a pro-inflammatory state, and insulin resistance associated with Metabolic Syndrome, said method comprising the step of:

administering to a patient suffering with Metabolic Syndrome a therapeutically effective amount of a central acting dopamine agonist to simultaneously treat hypertension, hypertriglyceridemia, a pro-inflammatory state, and insulin resistance.

2. The method of claim 1, wherein said method further comprises treating obesity.

3. The method of claim 1, wherein the central acting dopamine agonist is bromocriptine.

4. The method of claim 1, wherein the central acting dopamine agonist is administered in combination with an acceptable pharmaceutical carrier.

5. The method of claim 4, wherein the pharmaceutically acceptable carrier is selected from the group consisting of water, saline solution, gelatin, lactose, starch, magnesium stearate, talc, plant oils, gums, alcohol, petroleum jelly, and combinations thereof.

6. The method of claim 1, wherein said therapeutically effective amount of a central acting dopamine agonist ranges from 0.001 mg per kg body weight to 0.2 mg per kg body weight.

7. A method of simultaneously treating hypertension, hypertriglyceridemia, a pro-inflammatory state, and insulin resistance associated with Metabolic Syndrome, said method comprising the step of:

administering to a patient suffering with Metabolic Syndrome a therapeutically effective amount of a pharmaceutical composition comprising bromcriptine and a pharmaceutically

acceptable carrier to simultaneously treat hypertension, hypertriglyceridemia, a pro-inflammatory state, and insulin resistance.

8. The method of claim 7, wherein said method further comprises treating obesity.

9. The method of claim 7, wherein the pharmaceutically acceptable carrier is selected from the group consisting of water, saline solution, gelatin, lactose, starch, magnesium stearate, talc, plant oils, gums, alcohol, petroleum jelly, and combinations thereof.

10. The method of claim 7, wherein said therapeutically effective amount of said pharmaceutical composition ranges from 0.001 mg per kg body weight to 0.2 mg per kg body weight.

11. The method of claim 1, wherein in said pharmaceutical composition, said bromocriptine ranges from 0.001 mg per kg body weight to 0.2 mg per kg body weight.